Impaired humoral immunity is associated with prolonged COVID-19 despite robust CD8 T cell responses.
Impaired humoral immunity is associated with prolonged COVID-19 despite robust CD8 T cell responses.
复制标题
DOI：
10.1016/j.ccell.2022.05.013
复制
发表时间：
2022-07-11
期刊：
影响因子：
50.3
通讯作者：
Vardhana, Santosha A.
中科院分区：
文献类型：
--
作者：
Lyudovyk, Olga;Kim, Justin Y.;Qualls, David;Hwee, Madeline A.;Lin, Ya-Hui;Boutemine, Sawsan R.;Elhanati, Yuval;Solovyov, Alexander;Douglas, Melanie;Chen, Eunise;Babady, N. Esther;Ramanathan, Lakshmi;Vedantam, Pallavi;Bandlamudi, Chaitanya;Gouma, Sigrid;Wong, Philip;Hensley, Scott E.;Greenbaurn, Benjamin;Huang, Alexander C.;Vardhana, Santosha A.
免疫失调如何影响癌症患者从COVID-19感染中恢复仍不清楚。我们分析了103名既往感染COVID-19的患者的细胞和体液免疫应答，其中超过20%的患者病毒清除延迟。延迟清除与核衣壳和刺突蛋白抗体的丧失以及功能性T细胞应答的代偿性增加相关。对外周血样本的高维分析表明，在长期疾病患者中，CD 8+效应T细胞分化增加，COVID特异性T细胞受体（TCR）库广泛但收敛性差。相反，具有CD 4+显性免疫表型的患者的长期疾病发生率较低，并表现出深度和高度选择性的COVID相关TCR库，与有效的病毒清除和T细胞记忆的发展一致。这些结果强调了B细胞和CD 4 + T细胞在促进持久的SARS-CoV-2清除中的重要性，以及协调细胞和体液免疫对长期疾病控制的意义。Lyudovyk等人分析癌症患者清除SARS-CoV-2所需的免疫因素。他们观察到，尽管有广泛和功能性的抗病毒CD 8 + T细胞应答，但体液免疫受损的患者的病毒清除延迟。然而，B细胞缺陷型患者具有稳健的CD 4 + T细胞应答，通常能够实现有效的病毒清除。
How immune dysregulation affects recovery from COVID-19 infection in patients with cancer remains unclear. We analyzed cellular and humoral immune responses in 103 patients with prior COVID-19 infection, more than 20% of whom had delayed viral clearance. Delayed clearance was associated with loss of antibodies to nucleocapsid and spike proteins with a compensatory increase in functional T cell responses. High-dimensional analysis of peripheral blood samples demonstrated increased CD8+ effector T cell differentiation and a broad but poorly converged COVID-specific T cell receptor (TCR) repertoire in patients with prolonged disease. Conversely, patients with a CD4+ dominant immunophenotype had a lower incidence of prolonged disease and exhibited a deep and highly select COVID-associated TCR repertoire, consistent with effective viral clearance and development of T cell memory. These results highlight the importance of B cells and CD4+ T cells in promoting durable SARS-CoV-2 clearance and the significance of coordinated cellular and humoral immunity for long-term disease control. Lyudovyk et al. analyze immunological factors required for SARS-CoV-2 clearance in patients with cancer. They observe delayed viral clearance in patients with impaired humoral immunity despite broad and functional antiviral CD8+ T cell responses. However, B cell-deficient patients with robust CD4+ T cell responses were frequently able to achieve efficient viral clearance.
登录
查看更多内容
影响因子：
30.8
作者：
Emerson, Ryan O.;DeWitt, William S.;Robins, Harlan S.
通讯作者：
Robins, Harlan S.
血液学恶性肿瘤和COVID-19患者的临床特征和结果表明，延长SARS-COV-2运输是一个重要问题。
影响因子：
3.5
作者：
Arcani R;Colle J;Cauchois R;Koubi M;Jarrot PA;Jean R;Boyer A;Lachamp J;Tichadou A;Couderc AL;Farnault L;Costello R;Venton G;Kaplanski G
通讯作者：
Kaplanski G
影响因子：
7.5
作者：
Jiménez M;Roldán E;Fernández-Naval C;Villacampa G;Martinez-Gallo M;Medina-Gil D;Peralta-Garzón S;Pujadas G;Hernández C;Pagès C;Gironella M;Fox L;Orti G;Barba P;Pumarola T;Cabirta A;Catalá E;Valentín M;Marín-Niebla A;Orfao A;González M;Campins M;Ruiz-Camps I;Valcárcel D;Bosch F;Hernández M;Crespo M;Esperalba J;Abrisqueta P
通讯作者：
Abrisqueta P
影响因子：
82.9
作者：
Gao Y;Cai C;Grifoni A;Müller TR;Niessl J;Olofsson A;Humbert M;Hansson L;Österborg A;Bergman P;Chen P;Olsson A;Sandberg JK;Weiskopf D;Price DA;Ljunggren HG;Karlsson AC;Sette A;Aleman S;Buggert M
通讯作者：
Buggert M
影响因子：
64.5
作者：
Hoffmann M;Arora P;Groß R;Seidel A;Hörnich BF;Hahn AS;Krüger N;Graichen L;Hofmann-Winkler H;Kempf A;Winkler MS;Schulz S;Jäck HM;Jahrsdörfer B;Schrezenmeier H;Müller M;Kleger A;Münch J;Pöhlmann S
通讯作者：
Pöhlmann S